FGFR2 fusion

FGFR inhibition in #urothelialcarcinoma #bladdercancer at #ASCO23 - 1)The THOR Phase III trial in advanced #urothelialcarcinoma (UC) with FGFR2/3 mutations/fusions: Erdafitinib extended overall survival (OS) v taxane or vinflunine chemotherapy (median 12.1 v 7.8 mo, HR 0.64,… https://t.co/AM7hNC5Db6 (@sonpavde)

⁦@MiteshBorad⁩ presents Phase I of FGFR2 inhibitor (RLY-4008) in cholangio & solid tumors. No MTD. Glad pan-FDFRi refractory FGFR2+ fusion cholangio included w ORR 21% w 70mg or greater & 11% <70mg. ⁦@ArndtVogel⁩ discussed potential for “strategic sequencing” #ASCO23 (@MadisonConces)

🔥ESMO-MCBS monthly approval UPDATE🔥 ✅CHMP adopted positive opinion for Futibatinib 🎯💊in FGFR2-fusion+ #cholangiocarcinoma based on FOENIX-CCA2 👉ESMO-MCBS score of 3 https://t.co/6PnAvHNYyf @myESMO @EASLedu @CcaEns @OncoAlert #livertwitter https://t.co/sgw4tbxVHX (@ArndtVogel)

🔥ESMO-MCBS monthly approval UPDATE🔥 ✅CHMP adopted positive opinion for Futibatinib 🎯💊in FGFR2-fusion+ #cholangiocarcinoma 👉ESMO-MCBS score of 3, based on FOENIX-CCA2 https://t.co/6PnAvHNYyf @myESMO @EASLedu @CcaEns @OncoAlert #livertwitter (@ArndtVogel)

🔥CHMP ISSUES POSITIVE OPINION FOR FUTIBATINIB FOR THE TREATMENT OF ADULTS WITH CHOLANGIOCARCINOMA 👉Good news and more options for patients with FGFR2 fusions @myESMO @OncoAlert @EASLedu @CcaEns (@ArndtVogel)

🔥Specific recognition of an FGFR2 fusion by TILs from a patient with metastatic #cholangiocarcinoma @jitcancer https://t.co/1YJlIOrDWS 👉FGFR2 fusions can be immunogenic 🤔Proof of concept to explore T cell-based therapy targeting FGFR2 fusions in BTC @myESMO @EASLedu… https://t.co/9ahgt9mooB (@ArndtVogel)

What drug is this patient on...? A patient with intrahepatic cholangiocarcinoma with FGFR2 fusion. Responding nicely to pemigatinib, an FDA-approved FGFR inhibitor. Tumor calcifications are sometimes seen and here is an example of that. Remember, sequence ALL biliary cancers!!! (@OncoThor)

Great to see this collaborative study between @UPMCHillmanCC @JHUPath @MayoClinicPath @CLEClinicLabs. Tweetorial coming out soon, but if you are interested in Actionable Fusion Genes (FGFR2, ALK, BRAF, NRG1, RET and others) in #PancreaticCancer look to ITPNs of the #Pancreas. (@PancPathologist)

We have similarly seen a predilection for FGFR2 fusions and female patients among iCCAs. One wonders if this can be associated with specific precursor neoplasms? #Cholangiocarcinoma (@PancPathologist)

🔥The Co‐mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion‐Driven Cholangiocarcinoma @HEP_Journal https://t.co/TC5aUZdkWK 🔥Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma @trendscancer https://t.co/JCPSnToFCc (@ArndtVogel)

👉In depth analysis of co-alterations in 713 pts with FGFR2 fusions 🔥Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma @JHepatology https://t.co/f0d7M2pqQD 👉We need data on the impact of co-alterations on the efficacy of 🎯💊 (@ArndtVogel)

11/19 #TumorBoardTuesday 👨🏽‍🏫Mini tweetorial 6👨🏻‍🏫 💉Erdafitinib 👍🏽@US_FDA accelerated approval erdafitinib in platinum-refractory met #UrothelialCarcinoma with FGFR2/3 mut or fusion 19 (see figure👇🏽) ✨phase 3 THOR trial ongoing 📚https://t.co/CCNB5pXn4N 🔗https://t.co/PbJFN0gqkF (@rafee_talukder)

Watch: @SKamath_MD discusses the prevalence of FGFR2 fusions or rearrangements in cholangiocarcinoma. #oncology https://t.co/aJrfr3CdBK (@OncLive)

🔥Precision oncology for biliary tract tumors: it’s written in blood! @Annals_Oncology https://t.co/bx2U8tcO06 👉High concordance between tissue & liquid biopsy ❗️But be aware: FGFR2 fusions are challenging @myESMO @OncoAlert @EASLedu #livertwitter https://t.co/ESmAGSlgDV (@ArndtVogel)

🔥FGFR mRNA in cholangiocarcinoma & its correlation with FGFR2 fusion status and immune signatures🔥 @CCR_AACR https://t.co/wbOxQY5MZw 👉FGFR2 fusion = low PDL-1 & high CSF1R expression 👉Oncodriver impact iTME 👉Supporting our ongoing ADVANCE phs-2 in #CCA @myESMO @EASLedu (@ArndtVogel)

A survival benefit was elicited with the use of pemigatinib when used for patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement. #lcsm @MSKCancerCenter @GABOUALFA https://t.co/3zw9NXWgap (@TargetedOnc)

Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma using a novel cfDNA algorithm for treatment w RLY-4008, a highly selective irreversible FGFR2 inhibitor #ENAsymp22 @AliSchram @OncoAlert @Relay_Tx (@VivekSubbiah)

🎯On behalf of all co-investigators presenting👉Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma using a novel cfDNA algorithm for treatment w RLY-4008, a highly selective irreversible FGFR2 inhibitor #ENAsymp22 @AliSchram @OncoAlert @Relay_Tx (@VivekSubbiah)

In the FIGHT-101, study of pemigatinib we had a patient with FGFR2 fusion + pancreatic cancer who achieved a partial response. Yes, @Aiims1742 we need to look 👀 for these fusions #PrecisionOncology https://t.co/Tj8hYCcGu8 https://t.co/8Xn6qnZLL0 (@VivekSubbiah)

Pemigatinib showed a strong survival benefit in patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement, according to final results of a study presented at #ILCA22. @GABOUALFA @MSKCancerCenter https://t.co/jA8ESAluK8 (@TargetedOnc)

🔥Comprehensive characterization of KRAS WT #pancreaticcancer🔥 @NatureComms https://t.co/Z8m292E6Bg 👉high freq. of fusions (6-67%)>BRAF, NRG1, NTRK, FGFR2 👉R5A2, PROX1 & chr1q amplification > druggable 🎯? 👉transcriptome similar to #CCA 🧐KRAS testing in #PDAC key @myESMO (@ArndtVogel)

Adding another recent #KRAS WT #PDAC case w/#FGFR2 fusion w/exceptional response to #erdafitinib to the collection from our @CSCancerCare team @DrHendifar @DrArsenOsipov #pancsm @PrecOncNews https://t.co/9o8kNJFLmS @JNCCN @TumorBoardTues (@jgong15)

🔥FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope? 🔥 https://t.co/Pjgui96OTQ ✅4 intersting cases responding to FGFRi 👉all KRAS WT with comparable long survival 🧐non-typical fusion partners 🎯Early NGS in KRAS WT #PDAC❗️ @myESMO @OncoAlert (@ArndtVogel)

🔥just published: Genomic architecture of FGFR2 fusions in #cholangiocarcinoma and its implication for molecular testing🔥 @BrJCancer https://t.co/aqDgYP7Ta9 👉Our detailed overview on technical & biological aspects of FGFR2 fusion detection @myESMO @OncoAlert @enscca @EASLedu (@ArndtVogel)

Another kind of FGFR2; not the fusions🧬 but amplifications⏫ relevant to Upper GI cancers. The drug here is BEMA (Bemartizumab). Monoclonal antibody. In the HER2➖ ~30%. The test actually is IHC🔬 or #ctDNA in the actual trial. https://t.co/lqDMqrrrWL (@pashtoonkasi)

JUST IN: @US_FDA approves to futibatinib (20 mg/d) in metastatic intrahepatic cholangiocarcinoma w/FGFR2 gene fusions/rearrangements. ORR was 42% in TAS-120-101 trial with top AEs: nail toxicity, MSK pain/GI. @ASCO @OncoAlert (@DrChoueiri)

🔥comprehensive study on ctDNA in #cholangiocarcinoma 🔥 @Annals_Oncology https://t.co/W2XI9ZDq4C ✅1,671 pts. Guardant360 🎯GA in 44% 💪Concordance⬆️ btw cfDNA & tissue for IDH1 and BRA, but ⬇️ for FGFR2 fusion 18%🤨 👉Excellent, but know limitations 👏@lipika_goyal @myESMO ()

There are reports of FGFR2 fusions in hepatocellular carcinoma and non small cell lung cancer. It is not BCR-ABL and CML . (@SuyogCancer)

For patients with solid tumors, there is a compassionate access program for erdafitinib, but i think that's for FGFR2 and FGFR3 fusions only. Tagging @drakhilkapoor1 for any additional information. (@VanitaNoronha)

🔥Detection of FGFR2 fusions is challenging❗️ https://t.co/aqDgYOQiiB ✅🔥🎯in #Cholangiocarcinoma #PancreaticCancer... 👇we provide detailed analysis on genomic architecture of FGFR2 fusions & implication for molecular testing 👉know your NGS Panel @myESMO @enscca @OncoAlert (@ArndtVogel)

It’s absolutely amazing to see how many active compounds targeting FGFR2 fusions are available for our patients with #BiliaryTractCancer - great slide by @ArndtVogel ⭐️ #@OncoAlert 🚨#PrecisionMedicine @pashtoonkasi @GABOUALFA @VivekSubbiah (@BenWestphalen)

Research on FGFR2 fusion in #cholangiocarcinoma is an incredible experience. Doing research with @SaborowskiAnna doi: 10.1002/hep.31799 Discuss data with #OresteSegatto https://t.co/sZckA4AktA Being part of FIGHT-202 —> getting approval by EMA/ FDA 🙏 @myESMO @CcaEns (@ArndtVogel)

🔥FGFR2 alterations in #cholangiocarcinoma 👉fusion: FGFR2 intron 17/exon 18 breakpoint; partner is known or novel/in-frame with FGFR2 👉rearrangement: gene is out-of-frame with ex. 17 👉truncation: loss of neg. regulatory element 👉In-Frame Deletion.. ✅all druggable @myESMO (@ArndtVogel)

FOENIX-CCA2 Analysis Confirms Safety and Efficacy of Futibatinib for Advanced Intrahepatic Cholangiocarcinoma With FGFR2 Fusions/Rearrangements https://t.co/XIJp391uWH @asco #ASCO22 (@GlopesMd)

🚨Happening now: Abstract 4009: Updated results of the #FOENIXCCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma #iCCA harboring #FGFR2 fusions/rearrangements. #HPBCSM 📍Hall D1 @rachnatshroff #ASCO22 @ASCO (@Charbel_matar1)

Interesting post-hoc analysis of FIGHT-202. Relative short PFS on CTx for patients with FGFR2 fusion —> sensitivity of tumors with draggable GA to CTx should be explored. https://t.co/UKiv1x1NZf #cholangiocarcinoma #precisiononcology #livercancer @myESMO (@ArndtVogel)

Interesting post-hoc analysis of FIGHT-202. Relative short PFS on CTx for patients with FGFR2 fusion —> sensitivity to CTx of tumors with druggable GA should be explored. https://t.co/UKiv1x1NZf… #cholangiocarcinoma #precisiononcology #livercancer @myESMO (@ArndtVogel)

MUST SEE TV @rachnatshroff on precision oncology in #cholangiocarcinoma. *Importance of biomarker testing *#FGFR inhibitor infigratinib in #FGFR2-fusion-positive CC. Presented by @melinda_bachini for @curecc #cholangiotwitter #livertwitter #onctwitter https://t.co/r6OGBu5riE (@intraccsurvivor)

Erdafitinib for Advanced #urothelialcarcinoma and tumor FGFR2/3 mutations/fusions- updated results-101 treated-ORR 40%, median PFS 5.5 months (mo), DOR 6 mo (31% 1-year DOR), time to response 1.4 mo, OS 11.3 mo @y_loriot @AndreaNecchi-https://t.co/6ocRJgnLp0 @practiceupdate (@sonpavde)

In @Cancer_Cell Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic #cholangiocarcinoma https://t.co/mDz3LbrtxM Not unexpectedly, FGFR2 fusions generate neoantigens that can be potentially targeted. Cc: @JavleMilind @rachnatshroff @curecc (@Aiims1742)

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study 2/4 @JavleMilind @GABOUALFA https://t.co/mR8QgQQRXq (@VivekSubbiah)

Promising role of ctDNA in advanced UC for patient selection based on FGFR2/3 mut/fusion (also separate promising data in the adjuvant setting) @tompowles1 @Uromigos Enjoy the read on our teamwork with @sonpavde et al. @OncoAlert @BladderCancerUS @FaltasLab @scientistatlrge (@PGrivasMDPhD)